E-Star BioTech has dosed the first patient in its BOLD-HTN Phase 2 clinical trial, evaluating MANP for resistant hypertension treatment, marking a significant milestone in cardiovascular medicine.
A clinical trial is underway to assess the efficacy of low-dose dobutamine in patients with acute myocardial infarction (AMI) at intermediate to high risk.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.